NASDAQ:ZVSA ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis → Crypto Millionaire Says: “Buy This $11 AI Coin.” (From InvestorPlace) (Ad) Free ZVSA Stock Alerts $5.46 +0.09 (+1.68%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$5.18▼$5.5250-Day Range$4.99▼$9.5552-Week Range$4.44▼$180.25Volume47,104 shsAverage Volume542,559 shsMarket Capitalization$4.15 millionP/E RatioN/ADividend YieldN/APrice Target$120.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get ZyVersa Therapeutics alerts: Email Address ZyVersa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,097.8% Upside$120.00 Price TargetShort InterestHealthy2.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.29Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($15.05) to ($25.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.84 out of 5 stars 3.5 Analyst's Opinion Consensus RatingZyVersa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageZyVersa Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about ZyVersa Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.08% of the float of ZyVersa Therapeutics has been sold short.Short Interest Ratio / Days to CoverZyVersa Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ZyVersa Therapeutics has recently decreased by 96.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldZyVersa Therapeutics does not currently pay a dividend.Dividend GrowthZyVersa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZVSA. Previous Next 3.5 News and Social Media Coverage News SentimentZyVersa Therapeutics has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ZyVersa Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for ZVSA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added ZyVersa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ZyVersa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.74% of the stock of ZyVersa Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.91% of the stock of ZyVersa Therapeutics is held by institutions.Read more about ZyVersa Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ZyVersa Therapeutics are expected to decrease in the coming year, from ($15.05) to ($25.45) per share.Price to Book Value per Share RatioZyVersa Therapeutics has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAmerica’s worst nightmare?What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late.Click here to watch this bombshell exposé now. About ZyVersa Therapeutics Stock (NASDAQ:ZVSA)ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.Read More ZVSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZVSA Stock News HeadlinesMay 11 at 5:00 AM | americanbankingnews.comZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Down 96.6% in AprilApril 29, 2024 | msn.comWhat's Going On With ZyVersa Stock?April 29, 2024 | finance.yahoo.comZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s DiseaseApril 29, 2024 | globenewswire.comZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's DiseaseApril 4, 2024 | globenewswire.comZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with DiabetesApril 3, 2024 | benzinga.comZyVersa Therapeutics Stock (NASDAQ:ZVSA), Quotes and News SummaryMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed: ZyVersa Therapeutics’ Promising Pipeline and Strategic AdvancementsMarch 25, 2024 | globenewswire.comZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 18, 2024 | globenewswire.comZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney DiseaseMarch 14, 2024 | finance.yahoo.comZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024March 14, 2024 | globenewswire.comZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024March 13, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: ACELYRIN, INC. (SLRN), ZyVersa Therapeutics (ZVSA)February 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for ZyVersa Therapeutics Amid Promising Inflammatory and Metabolic Syndrome TreatmentsFebruary 29, 2024 | globenewswire.comZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat ObesityFebruary 28, 2024 | finance.yahoo.comZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its ComplicationsFebruary 28, 2024 | globenewswire.comZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its ComplicationsFebruary 26, 2024 | msn.comWhat In The World Is Going On With ZyVersa Therapeutics (ZVSA) Stock?February 26, 2024 | investorplace.comWhy Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?February 22, 2024 | finance.yahoo.comZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic OptionFebruary 22, 2024 | globenewswire.comZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic OptionFebruary 14, 2024 | finance.yahoo.comZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological DiseasesFebruary 14, 2024 | globenewswire.comZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological DiseasesFebruary 7, 2024 | finance.yahoo.comZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key MilestonesJanuary 31, 2024 | finance.yahoo.comZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 DiabetesJanuary 24, 2024 | finance.yahoo.comZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s DiseaseSee More Headlines Receive ZVSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ZVSA CUSIPN/A CIK1859007 Webwww.zyversa.com Phone754-231-1688FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$120.00 High Stock Price Target$120.00 Low Stock Price Target$120.00 Potential Upside/Downside+2,097.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-233.62% Return on Assets-171.17% Debt Debt-to-Equity RatioN/A Current Ratio0.33 Quick Ratio0.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$88.98 per share Price / Book0.06Miscellaneous Outstanding Shares760,000Free Float752,000Market Cap$4.15 million OptionableNot Optionable Beta0.67 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Stephen C. Glover (Age 64)Co-Founder, Chairman, CEO & President Comp: $775kMr. Peter Wolfe (Age 56)CFO & Secretary Comp: $477.5kMs. Karen A. Cashmere (Age 72)Chief Commercial Officer Comp: $410kMs. Melda Uzbil O'connellSenior Vice President of Corporate DevelopmentDr. Pablo A. Guzman FACC (Age 74)M.D., Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board Key CompetitorsSeelos TherapeuticsNASDAQ:SEELKazia TherapeuticsNASDAQ:KZIANexImmuneNASDAQ:NEXIPetros PharmaceuticalsNASDAQ:PTPIBright Minds BiosciencesNASDAQ:DRUGView All Competitors ZVSA Stock Analysis - Frequently Asked Questions Should I buy or sell ZyVersa Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ZyVersa Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZVSA shares. View ZVSA analyst ratings or view top-rated stocks. What is ZyVersa Therapeutics' stock price target for 2024? 1 brokers have issued 12-month target prices for ZyVersa Therapeutics' stock. Their ZVSA share price targets range from $120.00 to $120.00. On average, they expect the company's share price to reach $120.00 in the next twelve months. This suggests a possible upside of 2,097.8% from the stock's current price. View analysts price targets for ZVSA or view top-rated stocks among Wall Street analysts. How have ZVSA shares performed in 2024? ZyVersa Therapeutics' stock was trading at $9.00 at the beginning of the year. Since then, ZVSA stock has decreased by 39.3% and is now trading at $5.46. View the best growth stocks for 2024 here. When did ZyVersa Therapeutics' stock split? ZyVersa Therapeutics shares reverse split on the morning of Friday, April 26th 2024. The 1-10 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of ZyVersa Therapeutics? Shares of ZVSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZVSA) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityNot Trump. Not Biden. But ___________.The Freeport SocietyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
